The Centre for Medicines Discovery aims to catalyse the discovery and development of new medicines for patients.
2 November 2022
The Bullock group was delighted to welcome the FOP Friends charity and patient families to the CMD in October. FOP (fibrodysplasia ossificans progressiva) is a congenital syndrome of extraskeletal bone formation caused by a gain of function mutation in the ACVR1/ALK2 protein kinase. Families were given a lab tour and updated on the latest research news, including progress of the “STOPFOP” clinical trial developed by the Bullock group and collaborators.
28 June 2022
The Rainwater Charitable Foundation announces partnership with drug discovery teams at the University of Oxford.
27 June 2022
Massive congratulations to our DPhil student Amber Truepenny who won the inaugural Jamie Ferguson Chemistry Innovation Award. It’s a real testament to all her hard work on an exciting and challenging project - watch this space!
The Target Enabling Package on #TREM2 for #AlzheimersDisease includes investigations on binding modes & functional activity of scFv antibody fragments. In collaboration with @ARUK_ODDI @karolinskainst @thesgconline @KTHresearch @EisaiUS & VivaBiotech. https://doi.org/10.5281/zenodo.5256633
Biallelic PRMT7 pathogenic variants are associated with a recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities.
Cali E. et al, (2022), Genet Med
Single-cell transcriptomics defines an improved, validated monoculture protocol for differentiation of human iPSC to microglia.
Washer SJ. et al, (2022), Sci Rep, 12
Pathogenic Interleukin-10 Receptor Alpha Variants in Humans — Balancing Natural Selection and Clinical Implications
Aschenbrenner D. et al, (2022), Journal of Clinical Immunology
Following the recent launch of the government’s Living with COVID-19 guidance, the University has decided that current health measures will remain in place until 26 March in order to avoid disruption during term time. Protect one another from infection. There is still a high level of transmission of the virus, so the risk of infection remains high. COVID-19 can still pose a serious health threat to certain groups. Be considerate to them by continuing to follow the COVID-19 precautions.
Please continue to take the following actions until 26 March to minimise disruption to University life and academic studies this term:
- Test twice a week and if you have symptoms. Remember to report all your LFD results to both the University’s Early Alert Service and the NHS. If you have tested positive for COVID-19 or have symptoms, stay at home and avoid contact with others.
- Wear a face covering (unless exempt) when asked. Departments, as well as individual members of teaching staff, can continue to mandate face coverings in teaching and learning environments (unless individuals are exempt). Face coverings are strongly encouraged in libraries and should be worn when moving around University buildings.
- Let fresh air in when indoors: keeping windows and doors open increases ventilation and significantly reduces the spread of COVID-19. Please keep them open, particularly in areas which are poorly ventilated or where signs indicate the need to do so.
- Get your booster jab as soon as you’re eligible, and get a free flu jab if you can
Please refer to the University of Oxford Health page for updated health guidance.